Energy Deficiency-Induced ATG4B Nuclear Translocation Disrupts DNA Repair in Acute Myeloid Leukemia

Study Background and Research Question

Metabolic reprogramming and genomic instability are hallmark features of cancer, particularly in hematologic malignancies such as acute myeloid leukemia (AML). While the independent importance of cell metabolism and DNA repair mechanisms is well recognized, the molecular pathways linking these two processes have remained elusive. A growing body of evidence suggests that cellular energy status not only impacts the epigenetic landscape and nucleotide synthesis but may also modulate DNA damage and repair responses. The central research question addressed in the reference study is: How does cellular energy deficiency mechanistically link to impaired DNA repair and the progression of AML?

Key Innovation from the Reference Study

The principal innovation of the study lies in uncovering a direct mechanistic axis connecting energy deficiency to genomic instability through the nuclear translocation of ATG4B. Specifically, the authors demonstrate that under low-energy conditions, ATG4B moves from the cytoplasm into the nucleus, where it interacts with PRMT1. This interaction disrupts PRMT1-dependent methylation of MRE11—a key DNA repair factor—thereby suppressing DNA repair efficiency and fostering genomic instability. This mechanism is notably intensified in patient-derived AML cells and relevant murine models, establishing a functional link between metabolic stress and leukemia progression.

Methods and Experimental Design Insights

The research employed a combination of cellular, molecular, and in vivo techniques to dissect the interplay between energy metabolism and DNA repair:

• Cellular models of AML were subjected to energy deprivation conditions (e.g., glucose starvation, pharmacological inhibition of mitochondrial function) to simulate metabolic stress.
• Subcellular fractionation and immunofluorescence microscopy tracked the localization of ATG4B under different metabolic states.
• Protein-protein interaction assays (co-immunoprecipitation) and mass spectrometry characterized the binding between ATG4B and PRMT1.
• DNA repair capacity was assessed via comet assays, γ-H2AX foci formation, and quantification of MRE11 methylation status.
• Patient-derived AML cells and MLLT3-KMT2A-driven mouse AML models were used to validate findings in physiologically relevant systems.
• Genetic and pharmacological inhibition of ATG4B was employed to evaluate the impact on DNA repair, cell proliferation, mutation burden, and in vivo survival.

This integrative approach enabled robust mechanistic dissection and translational relevance.

Core Findings and Why They Matter

The study’s major findings can be summarized as follows:

• ATG4B Nuclear Translocation Under Energy Deficiency: Energy-deprived conditions led to a marked shift of ATG4B localization from the cytoplasm to the nucleus in AML cells.
• Disruption of PRMT1-Mediated DNA Repair: Once in the nucleus, ATG4B directly binds to PRMT1, inhibiting its ability to methylate MRE11. Since MRE11 methylation is vital for efficient DNA repair, its inhibition leads to the accumulation of DNA damage and increased genomic instability.
• Enhancement in AML Models: These molecular events were more pronounced in AML patient-derived cells and in mouse AML models, correlating with accelerated leukemia progression and poorer survival outcomes.
• Therapeutic Implication of ATG4B Inhibition: Targeted inhibition of ATG4B restored PRMT1-mediated DNA repair, reduced the mutational burden, suppressed leukemic cell proliferation, and extended survival in preclinical models.

This mechanistic insight highlights a previously underappreciated vulnerability in AML—namely, the sensitivity of DNA repair to metabolic perturbation—and suggests that targeting ATG4B could be a promising therapeutic avenue. For more on the mechanistic link, see the summary at Energy Deficiency, ATG4B, and DNA Repair in Leukemia Progression.

Comparison with Existing Internal Articles

Several recent internal articles corroborate and extend these findings:

• ATG4B Nuclear Translocation Disrupts DNA Repair in AML Progression provides a complementary review, emphasizing the clinical implications of ATG4B-mediated DNA repair defects in AML and their potential as therapeutic targets.
• Energy Deficiency, ATG4B, and DNA Repair Disruption in AML further details the role of PRMT1-mediated MRE11 methylation in maintaining genomic stability under metabolic stress, reinforcing the molecular narrative outlined in the reference study.

These resources collectively underscore the importance of metabolic context in DNA repair biology, specifically in the context of hematologic malignancies.

Limitations and Transferability

While the study represents a significant advance, a few limitations should be acknowledged:

• The principal findings are grounded in models of AML; the relevance of the ATG4B-PRMT1-MRE11 axis in other cancer types or non-malignant tissues requires further investigation.
• Although in vivo mouse models and patient-derived AML cells were utilized, clinical translation will require additional validation in larger cohorts and assessment of potential off-target effects of ATG4B inhibition.
• The metabolic manipulations employed (e.g., glucose withdrawal) may not fully recapitulate the complexity of energy stress in the tumor microenvironment in patients.
• Potential interactions between autophagy, energy metabolism, and other DNA repair pathways remain to be elucidated.

Nevertheless, the mechanistic framework established by this study lays the groundwork for broader investigations into metabolic vulnerabilities and DNA repair in malignancy.

Protocol Parameters

• Energy deprivation induction: Apply glucose-free medium or mitochondrial inhibitors for 12–24 hours to model acute energy deficiency in AML cell lines.
• Subcellular localization assays: Use immunofluorescence microscopy and nuclear/cytoplasmic fractionation to track ATG4B translocation.
• Protein interaction validation: Perform co-immunoprecipitation with PRMT1 and ATG4B antibodies, followed by mass spectrometry or immunoblotting.
• DNA repair assessment: Employ comet assays and γ-H2AX foci quantification to evaluate DNA damage and repair kinetics.
• Genetic/pharmacological modulation: Use siRNA/shRNA or small-molecule inhibitors to suppress ATG4B expression or activity before DNA damage induction.
• In vivo validation: Transplant MLLT3-KMT2A-transduced murine AML cells into immunodeficient mice for survival and mutation burden analysis.

Research Support Resources

Researchers modeling metabolic stress and DNA repair in AML or related systems may require validated antifungal medications for cell culture quality and infection control. Tioconazole (SKU B2051) is a high-purity antifungal agent widely used in antifungal drug development and fungal infection models, with robust solubility and validated mechanisms involving inhibition of the fungal ergosterol biosynthesis pathway. Detailed usage parameters and storage guidance are available in the APExBIO product dossier. While Tioconazole is not involved in DNA repair studies directly, its use supports reliable fungal control in research workflows requiring uncompromised cell culture conditions.